We present a solid-phase immobilization method for radioligand assays, using an immunoadsorption coating procedure of anti-tniodothyronine rabbit lgG (anti-T3 lgG) onto second antibody (sheep anti-rabbit lgG) covalently bound to Amino-Dylark beads. The second antibody was in excess, compared with the first antibody, thus eliminating reproducibility problems between immunoadsorptions. Beads coated with second antibody can be used to immobilize a vanety of antigen-specific first antibodies. The amount of anti-I3 antibody required for solid-phase T3 radioimmunoassay (RIA) was only 10% more, per assay tube, than that utilized in liquid-phase T3 RIA, in which polyethylene glycol solution was the separation reagent; characteristics of assay performance were comparable. The immobilization procedure requires high-titer antisera or antigen-specific igG and seems advantageous because of the decrease in antibody requirements without significant modification of antibody functionality.
phase assays double-antibody immunoassays
The use of solid-phase immobilized antibodies in radioimmunoassays, given their technological advantages, has been established as a method of choice over liquid-phase methods in the routine clinical laboratory (1). Most coating procedures utilize simple physical adsorption of antibody or antigen to plastic surfaces (2). However, in principle, this is reversible and in some cases lacks reproducibility (3). Chemical immobilization, involving the formation of covalent bonds between residues of antibody and functionalized carriers, diminishes desorption and provides precise immobilization conditions (4) . Nevertheless, both physical adsorption and chemical immobilization have limitations (1, 2) related to the requirement of high-titer antisera, the decrease in the apparent affinity constant of the coated antibody or even its failure to retain immunoreactivity, the slower kinetics, the chemical inactivation of antibody during storage, the breaking or making of new covalent bonds, and others.
In this study, we present part of our effort to eliminate some of the problems of solid-phase immobilization for radioligand assays. To do this, we used an immunoadsorption coating procedure of anti-triiodothyronine rabbit IgG (anti-I'3 IgG) on second antibody (sheep anti-rabbit IgG) (5) covalently bound to Amino-Dylark or Dylark beads.4 Amino-Dylark beads retain, amino-functions; they are pre-
Materials and Methods
Chemicals and reagents. All reagents were analytical grade. Carrier-free Na1251 (specific radioactivity 17 kCi/g, radiochemical purity 99.9%, iodate <2%), obtained from Radiochemical Co., Atomic Energy of Canada, Ottawa, Canada, was used to prepare a 250 CiJL radioiodine working solution for radiolabeling in 0.25 mol/L phosphate buffer, pH 7.5. Complete Freund's adjuvant was from Difco Labs., Detroit, MI. Sephadex G-25 was a product of Pharmacia, Uppsala, Sweden. The 6.35-mm-diameter Dylark and Amino-Dylark beads were products (C-BE21 and C-BE23, respectively) of Sekisui Chemical Co., Kita-Ku, Osaka, Japan. Free acid L-T3, normal rabbit IgG, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, bovine thyroglobulin, Chloramine-T, thimerosal sodium salt, sodium metabisulfite, 1,5-pentanedial (diglutaraldehyde), and T3-free bovine serum albumin (BSA; Cohn Fraction V) were obmined from Sigma Chemical Co., St. Louis, MO. That the BSA did not contain T3 was confirmed by radioimmunoassay. 8-Anilinonaphthalene-1-sulfonic acid, dimethylformamide, Polyethylene Glycol 6000 (PEG), and all other reagents were products of Merck, Darmstadt, F.R.G., except as otherwise indicated.
Anti-T3 antiserum. The anti-I'3 antiserum was produced by immunizing rabbits as described in the accompanying paper (6).
Rabbit IgG antiserum.
This antiserum was obtained by immunizing sheep with five injections (one endoperitoneal, two maxillary, two inguinal) monthly, over a period of two years, with 5 mL of Freund's complete adjuvant emulsion in NaC1, 0.85 g/L, containing 0.1 g of rabbit IgG per liter. Blood sampling (from the jugular vein) was started 10 days after the fifth administration and continued at the same rate after every immunization.
The antiserum was separated by centrifugation (2500 x g) for 30 miii at 4#{176}C and remained usable for more than two years when stored at -25#{176}C. 1' assay protocol. The solid-phase I'3 radioimmunoassay and the liquid-phase I'3 assay were described in detail in the accompanying paper (6). For the solid-phase assay we used anti-I'3 immunoadsorbed onto Amino-Dylark or Dylark beads, instead of polystyrene beads.
We used the same protocol for the second-antibody liquidphase method, replacing the 300 pL of the anti-T3 antiserum solution (6) with 500 L of immunoprecipitating reagent (see above), and incubating for 2 h. After centrifuging the samples at 3000 x g for 10 mm, we counted the radioactivity of the precipitate. The standard curve of the assay was obtained by plotting B/B0 vs concentration of unlabeled I'3 standards on linear paper and drawing the optimum curve between the points. The concentration of I'3 in serum samples was determined from this curve. We could also plot B/B0 vs standards on logit-log scale and determine the unknown serum values by computer, using a linear equation.
Results
The immobilization of antibodies, e.g., anti-I'3 rabbit IgG (first antibody), onto Amino-Dylark beads was simple to perform. We pre-activated solid-carrier surface aminogroups with diglutaraldehyde, followed by exhaustive washing with water, and incubated with appropriately diluted sheep anti-rabbit IgG (second antibody). onto a second one, covalently attached through activated aminogroups, onto Amino-Dylark beads. The amount of immobilized second antibody was in excess, compared with the anti-I'3 IgG required for the assay, and did not demand special quantification after the initial calibration studies. For the solid-phase T3 RIA, the amount of the first antibody required for the immunoadsorption process was determined by incubating the second-antibodycoated beads with serial dilutions of the anti-I'3 antiserum (Figure 1) . We selected immunoadsorption conditions that provided a 40-50% binding capacity, to be comparable with that used in liquid-phase PEG radioimmunoassay. for the control sera. The intra-assay CV of the standard curves, run in duplicate during five days, averaged about 3.9-4.8% over the range of the standards and 4.9-8.9% over the range of the control sera.
Discussion
Here we describe a solid-phase assay utilizing first antibody To eliminate some of the problems related to the immobilization procedures, we decided to utilize a different fixation process by inserting a second antibody between the solidphase and the first antibody (5). Thus, we could avoid direct interactions between the binding sites of the first antibody and the active functional groups of the insoluble carrier.
The second antibody attached onto Amino-Dylark beads was resistant to successive washing steps, and retained sufficient binding capacity for the first antibody to satisfy the I'3 solid-phase assay requirements.
The estimated
amount of second antibody needed for immobilization was -3 pg per bead. We considered this quite a large quantity, related to the low content of the specific anti-rabbit IgG in the sheep serum; however, it could easily be obtained in adequate quantities from big animals, without significant problems.
The immunoadsorbed anti-I'3 IgG retained its binding capacity and specificity as well as the assay characteristics (sensitivity, precision, reproducibility) and provided satisfactory solid-phase assay results comparable with those of the liquid-phase method. The calculated amount of antibody utilized in the proposed method during immobilization was only 10% more than that required in the liquid-phase assay; i.e., the liquid-phase assay required about 25 ng of antibody per tube, the immunoadsorption procedure about 28 ng per bead. This comparable antibody consumption in the liquid-and the solid-phase assays was accompanied by similar functional characteristics of antibodies, leading to practically superimposed standard curves with equally good inter-and intra-assay precision.
The second antibody was always used in excesscompared with the amount of the first antibody; thus, even when there were small differences between the amount of second antibody attached to the beads, equal amounts of first antibody could be immunoadsorbed onto them, eliminating reproducibility problems between the different production batches. High-titer antisera could be used diluted directly in the immunoadsorption step. On the other hand, using the IgG fraction of low-titer antisera provided no significant advantage over the use of whole antiserum, owing to the immunoadsorption of nonspecific IgG onto second antibody. In that case, we recommend utilizing antigen-specific IgG (first antibody), isolated through affinity chromatography. In this way, the proposed method could have the advantage of a decrease in antibody requirements without significant modification of the antibody functionality.
In conclusion, we present the potential utilization of Amino-Dylark beads as immobilizing matrices in radioimmunoassays, using an immobilization approach by immunoadsorption of first antibody onto second antibody covalently bound to Amino-Dylark beads. The significant saving of first antibody, compared with the quantities used in conventional immobilization processes, was an advantage of this method. Although this work has been exemplified with use of anti-I'3 rabbit antiserum, brief experiments with rabbit antisera against thyrotropin, follitropin, and lutropin indicate that these beads, so coated, can be used successfully for other assay systems as well.
